Identification of peroxisome proliferator-activated receptor ligands from a biased chemical library  by Brown, Peter J. et al.
Research Paper 909 
Identification of peroxisome proliferator-activated receptor 
ligands from a biased chemical library 
Peter J Brown’, Tracey A Smith-Oliver2, Paul S Charifsonl*, Nicholas CO 
Tomkinsonl, Adam M Fivushl, Daniel D Sternbach’, Laura E Wade2, Lisa 
Orband-Miller3, Derek J Parks3, Steven G Blanchard3, Steven A Kliewer2, 
JUrgen M Lehmann2 and Timothy M Willsonl 
Background: The peroxisome proiiferator-activated receptors (PPARs) were 
cloned as orphan members of the nuclear receptor superfamily of transcription 
factors. The identification of subtype-selective ligands for PPARa and PPARy 
has led to the discovery of their roles in the regulation of lipid metabolism and 
glucose homeostasis. No subtype-selective PPARG ligands are available and 
the function of this subtype is currently unknown. 
Results: A three-component library was designed in which one of the 
monomers was biased towards the PPARs and the other two monomers were 
chosen to add chemical diversity. Synthesis and screening of the library 
resulted in the identification of pools with activity on each of the PPAR 
subtypes. Deconvolution of the pools with the highest activity on PPARG led 
to the identification of GW 2433 as the first high-affinity PPARG ligand. 
13H]GW 2433 is an effective radioligand for use in PPARG competition- 
binding assays. 
Conclusions: The synthesis of biased chemical libraries is an efficient 
approach to the identification of lead molecules for members of sequence- 
related receptor families. This approach is well suited to the discovery of small- 
molecule ligands for orphan receptors. 
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Introduction 
The peroxisome proliferator-activated receptors (PPARs) 
are members of the superfamily of ligand-activated tran- 
scription factors that includes the receptors for the steroid 
hormones, retinoids, thyroid hormone and vitamin D [l]. 
The PPARs were originally cloned as orphan receptors for 
which the cognate hormones were unknown. Three recep- 
tor subtypes have been identified in humans and rodents, 
which are known as PPARa, PPARy, and PPARG. In addi- 
tion, three subtypes identified in Xenopus la&s have been 
designated PPARa, PPARy, and PPARB. Although the 
PPARa and PPARy subtypes appear to be homologous 
across species, it is currently unclear whether the PPARG 
and PPARB subtypes are functional homologs or two inde- 
pendent receptors [Z]. Like other members of the nuclear 
receptor family, the PPARs contain a DNA-binding domain 
(DBD) and a carboxy-terminal ligand-binding domain 
(LBD). The PPARs show > 85% sequence homology in the 
DBDs and > 60% sequence homology in the LBDs. 
Evidence that the PPARs may have different physiologi- 
cal functions was suggested from studying their tissue 
expression patterns. The PPARa subtype is expressed 
predominantly in liver, whereas PPARy is expressed pre- 
dominantly in fat, and PPARG is widely expressed in 
many tissues [3]. Following the identification of synthetic 
subtype-selective ligands for the PPARa and PPARy sub- 
types [4], pharmacological studies have established the 
role of PPARa in the regulation of hepatic lipid metabo- 
lism and the role of PPARy in the regulation of adipocyte 
function and glucose homeostasis [5,6]. Notably, the 
fibrate family of lipid-lowering drugs and the thiazolidine- 
dione family of anti-diabetic drugs function through 
binding to these two PPAR subtypes [7]. In addition, 
recent data suggest that PPARcx and PPARr may be 
hormone receptors for naturally occurring unsaturated 
fatty acids and certain eicosanoid metabolites [&lo]. 
Together, these studies suggest that one function of the 
PPARa and PPARy subtypes is to coordinate the body’s 
physiological response to dietary fatty acids through the 
regulation of lipid storage and catabolism [Z]. 
In contrast to the progress in elucidating the function of 
PPARa and PPARy, the physiological role of PPARG is 
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currently unknown. Although PPARG also responds to 
fatty acids in cell-based reporter gene assays [3,11,12], the 
lack of synthetic PPARG ligands has precluded detailed 
pharmacological study of this subtype. Thus, PPARG 
remains an orphan receptor of unknown function. The 
identification of synthetic PPARG ligands will allow phar- 
macological evaluation of the function of this subtype and 
may provide new opportunities for drug discovery. 
The technology of combinatorial chemistry is being 
widely employed to generate large diverse compound 
libraries for use in high-throughput screening for new lead 
generation [13,14]. LJsing similar chemical techniques, 
smaller libraries with lower compound diversity (so-called 
focused libraries) are often used to optimize the initial 
leads for potency and selectivity against a particular target 
[15]. We reasoned that, for orphan targets that belong to 
sequence-related receptor superfamilies, the screening of 
compound libraries biased toward the appropriate target 
class would be an efficient approach to lead generation. 
These libraries would be designed to have a compound 
diversity lower than a large combinatorial library but 
greater than a small focused library. We set out to test this 
concept through the solid phase synthesis (SPS) of biased 
compound libraries for the PPARs. Our goal was to iden- 
tify ligands with various subtype selectivities to support 
additional pharmacological investigation of receptor func- 
tion. We have designed and synthesized a library of 480 
trisubstituted urea analogs that incorporated a phenoxy- 
isobutyric acid monomer, commonly found in the fibrate 
class of lipid-lowering drugs (eg., bezafibrate, Figure 1) 
[lo]. This biased library showed activity on all three 
PPAR subtypes and allowed identification of GW 2433 as 
the first high-affinity PPARG ligand. 
Results 
Design and synthesis of the fibrate library 
The strategy for the construction of our library was based 
on the premise that the phenoxyisobutyric acid group 
found in the fibrate class of lipid-lowering drugs [lb] 
would be a biasing monomer toward the PPAR receptors. 
For example, we have shown that the fibrate GW 2331 
(Figure l), containing a lipophilic trisubstituted urea, is a 
high-affinity ligand for PPARa and PPARy [8]. In addi- 
tion, GW 2331 was a potent activator of xPPARP 
(Xenopzls), although it activated human and mouse PPARG 
only at doses > 1 FM [8]. Thus, we chose to design a 
library that added two points of diversity to the urea while 
maintaining the fibrate portion of the molecule (Figure 2). 
We have recently developed an SPS of fibrate analogs 
from the combination of an amino-substituted fibrate, a 
carboxylic acid and an isocyanate [ 171. For the current 
library, three fibrate monomers (Ml, Figure 2) were syn- 
thesized that contained 1, 2 or 3 methylenes between the 
phenyl ring and terminal amino group (1-3, Figure 3). The 
selection of the carboxylic acid (MZ, Figure 2) and iso- 
cyanate monomers (M3, Figure 2) was driven by our desire 
to explore the steric and electronic requirements for PPAR 
activity as well as to identify compounds with novel selec- 
tiviries. Starting from all commercially available carboxylic 
acids and isocyanates, the list of potential monomers was 
pared down by a series of logical steps. First, all of the 
monomers with molecular weight >300 or functionality 
incompatible with the solid phase chemistry were 
removed. Monomers with a large number of rotatable 
bonds were also eliminated. The remaining monomers 
were incorporated into a series of three-dimensional virtual 
libraries to calculate the electrostatic potential and mol- 
ecular surface of each theoretical product. Finally, a Space- 
fill experimental design [18] was used to select the 20 
carboxylic acids (MZ) and eight isocyanates (M3) that gave 
the most diverse library within the constraints of our 
design strategy (Figure 2). 
Each of the fibrate monomers (l-3) was loaded onto 
Sasrin resin and quantified by 9-fluorenylmethoxycar- 
bony1 (FMOC) analysis (Figure 3). We chose to synthe- 
size the library by pooling the resin-bound fibrate 
monomers and thus shorten the synthesis and screening 
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The design of the biased library. Ml is the biasing fibrate monomer. M2 and M3, derived from carboxylic acids and isocyanates, were chosen for 
diversity by experimental design. 
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[i 71. DMF, dimethyl formamide; TFA, 
trifluoroacetic acid; THF, tetrahydrofuran; DIG, 
1,3-diisopropylcarbodiimide; DMAP, 
4-dimethylaminopyridine. 
time. The resins (4) were pooled in equimolar quantities 
and then split into 20 aliquots. Each aliquot was depro- 
tected and then coupled with one of the 20 carboxylic 
acids, Following borane reduction, each aliquot was split 
into eight and reacted with the isocyanates. The final 
library of 480 fibrates (5) was synthesized in 8 x 10 parallel 
arrays in two microtiter plates. Each well contained a pool 
of three compounds resulting from the three fibrate 
monomers (Ml) with a unique combination of a carboxylic 
acid (MZ) and an isocyanate (M3; Figure 4a). 
PPAR activation profile of the fibrate library 
The fibrate library was screened at a concentration of 
5 FM in cell-based reporter gene assays against each of the 
three human PPAR subtypes. We chose to employ 
PPAR-GAL4 chimeric receptors since this assay format 
eliminated the background activity from endogenous 
receptors and allowed quantitation of relative activity 
across the three PPAR subtypes using the same reporter 
gene [19]. The activation data was expressed as the per- 
centage activation relative to 10 pM GW 2331, which 
showed 60-, 25 and l&fold activation of PPARa, PPARy 
and PPARG, respectively (data not shown). Notably, the 
library showed different activity profiles on the three 
PPAR subtypes (Figure 4b). The data revealed that 
PPARa was the most promiscuous of the three subtypes 
with more than half of the wells showing significant activ- 
ity (>25% of control). By contrast approximately one third 
of the wells were active on PPARy and less than one fifth 
were active on PPARG. The patterns of activity showed 
that aromatic M3 substituents (B, C, G, H in Figure 2) 
were active on all three subtypes, but that aliphatic M3 
substituents (A, E, F ;Figure 2) showed more sporadic 
activity especially on PPARy and PPARG. Among the MZ 
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Figure 4 
The fibrate library. (a) Array format of the 
fibrate library. Monomers M2 and M3 are 
shown on the axes of the plates. (b) Activation 
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Table 1 Identification of a high-affinity PPARG ligand 
PPARG activity of the deconvoluted pools. 
In part, our need to pool the fibrate monomers was dic- 
tated by the limitation in the throughput of the cell-based 
screening assay [ZO]. We have recently developed radio- 
ligands for the PPARcx [S] and PPARy [19] subtypes that 
allow rapid screening of compound libraries by standard 
competition-binding assays. The development of a compa- 
rable tool for the PPARF subtype would permit future 
libraries to be synthesized and screened as discrete com- 
pounds against all three receptors in parallel. For this 
reason we identified the six most active pools (Figure 4b; 
eB, eG, fs, kG, nl3, nG) and synthesized the individual 
components (Ml; & p, r) of each pool by SPS. The result- 
ing 18 compounds (Table 1) were assayed for activity on 
PPARG with the generation of full concentration-response 
curves. Only compounds possessing the fibrate monomer 
with the three methylene linker (‘y) were found to be 
potent activators of PPARG. Compounds ‘y&2 (GW 2433) 
and $G were the most potent with EC,, values of 160 nM 
and 250 r&l, respectively. Both compounds also showed 
significant activity on PPARa (EC,, -300-500 nM) but 
were inactive on PPARy (data not shown). 
Comoound* EC,, Ml) 
WB 
PeB 
W 
WG 
W 
‘yeG (GW 2433) 
afB 
W 
VB 
akG 
BkG 
ykG 
aIlB 
PnB 
VB 
anG 
PnG 
‘ynG 
> 10,000 
> 10,000 
1900 
> 10,000 
> 10,000 
160 
> 10,000 
6300 
6300 
> 10,000 
2000 
250 
> 10,000 
> 10,000 
7900 
> 10,000 
> 10,000 
1600 
*Structures can be constructed from the monomers in Figure 2. 
substituents, certain phenethyl groups (e, f, k, 1, n; Figure 
2) were active on all three subtypes, whereas other M2 
substituents were more discriminating. For example M2 
substituent (t) showed primarily PPARa activity, while 
substituent (0) showed activity on PPARa and PPARy but 
not PPARG. Certain combinations of M2 and M3 sub- 
stituents gave wells that showed predominant activity on a 
single subtype at the dose tested. Thus, tE was selective 
for PPARa, and IC was selective for PPARy. Other combi- 
nations of M2 and M3 substituents, such as kG, showed 
activity on all three PPAR subtypes. All of the pools with 
the highest PPARG activity (eB, eG, fB, kG, nB, nG in 
Figure 4) contained modified phenethyl h42 substituents 
(e, f, k, n in Figure 2) and showed some cross-reactivity 
with either PPARa or PPARy. 
From this initial analysis, the binding pockets of the 
PPAR subtypes appear to be grossly similar, but with 
subtle differences that can be exploited to identify 
subtype-selective ligands. Thus, PPARa is able to tolerate 
aliphatic M3 substituents (for example E) better than 
PPARy or PPARG, whereas only PPARy will tolerate large 
long-chain aliphatic M2 substituents (for example q or r, 
Figure 2). The PPARG pocket may be the least tolerant of 
different substituents since it showed the fewest active 
wells in the library. 
GW 2433 (w) was resynthesized by a solution phase 
method that allowed incorporation of radioactivity by tritia- 
tion of an unsaturated derivative (Figure 5). The bromo- 
ester (6) was subjected to a Heck reaction [Zl] with 
N-allylphthalimide, and the resulting product (7, Figure 5) 
was deprotected with hydrazine. The amine (8) was deriva- 
tized as the 2,4-dinitrosulfonamide (9), which was con- 
densed with Z-chloro-6-fluorophenylethanol by the method 
of Fukuyama et al. [ZZ]. Removal of the sulfonamide, reac- 
tion of the free amine (11) with 2,3-dichlorophenyliso- 
cyanare and saponification of the ester gave the unsaturated 
ureido-fibrate (12). Catalytic hydrogenation of 12 pro- 
ceeded smoothly to give GW 2433. Reduction of 12 with 
tritium gas gave [3H]GW 2433 with a specific activity of 
38 Ci/mmol. [3H]GW 2433 showed specific saturable 
binding to bacterially expressed PPARG (Figure 6a). A non- 
linear least squares fit of the data gave a K, of 13 nM. In 
competition-binding assays GW 2433 bound to PPARG with 
an apparent Ki of 40 nM, a value similar to the K, deter- 
mined by saturation binding (Figure 6b). GW 2433 also 
competed for [3H]GW 2331 binding to PPARa with an 
apparent Ki of 120 nM, but had no effect on [3H]BRL 
49653 binding to PPARy at doses up to 10 @I. 
Discussion 
The advent of the technology of combinatorial chemistry 
has provided new opportunities for the discovery of recep- 
tor ligands. The split/mix SPS method has been used to 
generate large chemical libraries of high diversity for 
screening against a wide range of targets [14,15]. As an 
alternative to the random approach, we have chosen to use 
SPS technology to generate compound libraries using a 
design methodology that biases the library toward families 
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Figure 5 
Solution synthesis of GW 2433. (i) Pd(OAc),, 
P(o-Tol),, MeCN, iV-allylphthalimide; yield 
66%. (ii) NH,NH,; yield 75%. (iii) 2,4- 
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fluorophenylethanol; yield 724/o. (v) 
HSCH,CO,H, Et,N; yield 78%. (vi) 2,3- 
Dichlorophenylisocyanate; then NaOH; yield 
48%. (vii) H,, 10% Pd-C; or T,,l 0% Pd-C; 
yield 93%. 
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of sequence-related receptors. This approach combines 
the insights of traditional medicinal chemistry with the 
benefits of rapid synthesis using solid phase chemistry. In 
the current example, since fibrates were known to have 
activity on multiple PPARs [&lo], phenoxyisobutyric acid 
was chosen as the biasing monomer that was present in 
each of the 480 members of the library. The screening 
results showed that this strategy led to the generation of a 
compound library in which ZO-50% of the wells showed 
activity on the different PPAR subtypes. By synthesizing 
the library in a parallel array format, the resulting patterns 
of activity contained information about the preferred 
monomers that led to subtype selectivity. Thus, we were 
able to rapidly identify those monomers which gave inter- 
esting PPAR selectivity profiles. For example, when M2 
was derived from 1-(4-methoxybenzyloxy)cyclohexane 
carboxylic acid (t) the resulting pools showed primarily 
PPARcx activity. When M2 was derived from lo-phenylde- 
canoic acid (q), however, the resulting pools showed pri- 
marily PPARr activity. In addition, unique combinations 
of M2 and M3 substituents that gave receptor selectivity 
were easily identified; tE was PPARa selective, and rC 
was PPARr selective. We chose not to deconvolute these 
pools, however, as we had already identified potent ligands 
for these two PPAR subtypes [8,19]. Instead we opted to 
deconvolute the six pools most active on PPARG. Resyn- 
thesis of the 18 individual compounds led to the identifica- 
tion of GW 2433 (@) as the most potent compound on 
PPARG, although it also showed significant PPARa activ- 
ity. Thus, the fibrate monomer with the 3-methylene 
linker appears to be permissive to PPARa and PPARG, but 
excludes PPARr activity. Identification of PPARG subtype 
selective compounds devoid of PPARa activity will 
require synthesis of new focused libraries to optimize the 
current leads. 
The activation profiles of the fibrate library demonstrated 
that PPARa is the most promiscuous of the subtypes, with 
PPAR? and PPARG showing more restricted patterns of 
activity. Historically, the fibrates were discovered through 
systematic evaluation of branched-chain fatty acids for 
their ability to regulate lipid metabolism in animals [23]. 
Therefore, it is interesting to note that recent evidence 
suggests that the PPARs function as hormone receptors 
for unsaturated fatty acids and their eicosanoid metabo- 
lites [&lo]. PPARa is expressed predominantly in the 
liver, where it regulates many of the genes involved in the 
catabolism of fatty acids. The PPARcl subtype may have 
evolved to respond to the wide range of naturally occur- 
ring fatty acids that are processed by the liver [24]. 
Notably, data generated with cell-based reporter gene 
assays showed that different classes of fatty acids activate 
PPARa, irrespective of chain length, degree of unsatura- 
tion or oxidation [25,26]. In comparison to PPARa, our 
data show that PPARG is activated by a more restricted 
range of synthetic compounds, which suggests that it may 
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Figure 6 
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(a) Saturation binding of [3H]GW 2433 to purified human PPARG 
LBD. Total binding (O), nonspecific binding (O), and specific binding 
(0) are shown. The inset shows a Scatchard transformation of the 
specific binding data. (b) Competition binding of GW 2433 to 
purified human PPARcl (O), PPARy (A), and PPARG (0) LBDs. Data 
are the mean of replicate determinations and error bars indicate the 
range of observations. 
respond to a more limited set of natural ligands. A similar 
conclusion was recently drawn through comparison of the 
fatty acids that enhance the binding of either PPARcx or 
PPARG to DNA, presumably through interaction with 
their LBDs [9]. Therefore, we speculate that although 
PPARG is the most widely expressed of the three sub- 
types, its more limited ligand specificity may result in a 
specialized physiological function. 
Our studies have resulted in the identification of the first 
high-affinity PPARG ligand, GW 2433. We have now gen- 
erated specific radioligands for all three PPAR subtypes: 
[3H]GW 2331, a PPARa radioligand [8]; [3H]BRL 49653, a 
PPARy radioligand [19]; and now [3H]GW 2433, a PPARG 
radioligand. These radioligands can be used in competi- 
tion-binding assays to rapidly screen for new PPAR 
ligands with improved subtype selectivities. In addition, 
we have shown that fibrate libraries generated by SPS 
deliver information about the relative ligand specificity of 
the PPARs, and may provide opportunities to develop 
potent and selective ligands for all three subtypes. 
Significance 
Historically, small-molecule drugs have been found that 
act on a limited number of protein classes. The nuclear 
receptor superfamily represents one of these target 
classes, incorporating the receptors for all of the steroid 
and retinoid drugs [27]. The existence of a large family of 
orphan nuclear receptors presents an exciting opportu- 
nity for the discovery of new drug molecules that act on 
these targets [ 1,281. Notably, identification of small-mol- 
ecule ligands is the rate-limiting step in the study of the 
pharmacology of orphan receptors and in establishing 
their role in normal physiology and disease processes. 
We have presented an approach to the identification of 
ligands for the orphan nuclear receptors based on the 
concept of biased chemical libraries. Our work has led 
to the identification of the first high-affinity PPARG 
ligand, GW 2433. The corresponding radioligand 
[3H]GW 2433 will be an important tool for the identifica- 
tion and characterization of PPAR subtype-selective 
ligands through competition-binding assays. Finally, our 
results show that the synthesis of biased chemical 
libraries containing a iibrate monomer provides a rich 
source of information about the ligand preferences 
among the three PPAR subtypes. 
Materials and methods 
Monomer selection 
The total number of commercially available carboxylic acids and iso- 
cyanates was reduced by the successive filters of molecular weight 
>300, incompatible reactive functionality, and multiply functionalized 
molecules. The resulting 660 carboxylic acids and 154 isocyanates 
were incorporated into the experimental design. For the design proto- 
col, Ml and either M2 or M3 were held constant as the variable 
monomer position was evaluated. When held constant the monomer 
choices for Ml, M2 and M3 were fibrate (2), phenylacetic acid and 
phenylisocyante, respectively. A virtual library was generated electroni- 
cally by splicing together SMILES strings [29] for the fixed monomers 
and the variable monomer and performing the necessary atom dele- 
tions and hybridization changes. A single conformer of each product 
was generated using CONCORD [30]. After 3D generation of the 
virtual library of products, each molecule was subjected to assignment 
of atom types and atomic charges followed by energy minimization 
using the MVP program [31]. Subsequently, the molecular surface was 
calculated for each molecule and the electrostatic potential was 
mapped onto this surface. Five properties were calculated for each 
molecule: the maximum, minimum, and mean electrostatic potentials, 
along with the hydrophilic and hydrophobic molecular surface areas. 
These five properties were standardized and subjected to Spacefill 
experimental design 1181 using the SAS module OPTEX [32] to 
choose 20 carboxylic acids and eight isocyanates. 
Synthesis of the fibrate library 
The general method for the synthesis of the fibrate library has been 
described previously [17]. Sasrin resin (0.89 mmollg) was loaded with 
the FMOC amino acids (1, 2, or 3), and the resulting resins combined in 
equimolar quantities following FMOC analysis of their relative loading. 
20 aliquots (125 mg, 54 pmol each) of the pooled resin (4, 
0.43 mmol/g) were deprotected with piperidine and then each coupled 
with one of the carboxylic acids corresponding to M2 (a-t). Following 
reduction with borane-THF complex each resin was subdivided into 
eight aliquots (15 mg each) and reacted with one of the isocyanates 
corresponding to M3 (A-H). The resulting 160 resins were cleaved with 
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1 Oo/, TFA in CH,CI,. The products (5) were placed into two microtiter 
plates in parallel arrays as depicted (Figure 4a) and dried to a thin film. 
HPLC-MS analysis (Waters NovaPak Cl 8, 3.9 x 100 mm, 1 O-l 00% 
MeCNIO.l% TFA-H,O, 0.4 mllmin, 220 nM, PVSciex API Ill, positive 
ion turbospray ionization) indicated that each well generated molecular 
ions consistent with the predicted products. Dimethylsulfoxide (DMSO) 
was added to each plate to give a stock solution of 1 O-2 M. The plates 
were replicated and frozen (-20%) for storage until biological testing. 
Deconvolution of active pools 
The FMOC amino acids (1, 2, or 3) were loaded onto Sasrin resin. SPS 
was conducted on the individual resins without pooling. The final resins 
were cleaved and the products purified by solid phase extraction 
(Bakerbond, SiOH) as described previously [17]. IH NMR and HPLC 
analysis (Hypersil ODS Cl8 3 pm, 4.6 x 60 mm, O-1000/, 
MeCN/O.l% TFA-H,O) indicated that the final products (aeB--tnG, 
Table 1) were >95% pure. 
Radio&and synthesis 
A solution of the unsaturated radioligand precursor (12; 4.7 mg, 
0.8 umol) in ethyl acetate (1.5 ml) was transferred to a tritiation flask 
containing 11 mg of 10% Pd-C. The flask contents were stirred with 
tritium gas (10 Ci) for 1 h. The catalyst was removed by filtration 
through a Nalgene filter using MeOH. Labile tritium was removed by 
successive rotary evaporations to dryness with MeOH (3 x 5 ml). The 
residue (195 mCi) was purified by HPLC (Ultrasphere ODS Cl 8, 
250 x 9.4 mm, 60-75% MeCN/O.l% TFA-H,O, 4 ml/min) to yield 
90 mCi of [sH]GW 2433 with a radiochemical purity of 96% and a 
specific activity of 38 Ci/mmol. [sH]GW 2433 was stored at -20°C as 
a solution in ethanol at a concentration of 1 mCi/ml. 
Characterization of GW 2433 
Isolated as a colorless glass. ‘H NMR (CD,OD): 6 7.6 (d, 1 H), 7.0-7.5 
(m, 7H), 6.8 (d, 2H), 3.6 (t, 2H), 3.2 (t, 2H), 3.1 (t, 2H), 2.55 (t, 2H), 1.9 
(m, 2H), 1.55 (s, 6H). Electrospray-MS (m/z-H): 579, 581, 583. Analyti- 
cal HPLC (Hypersil BDS Cl 8 5 u, 4.2 x 100 mm, O-l 00% MeCNIO.l o/, 
TFA-H,O): R, 7.0 min at 2 mllmin, purity >95% at 254, 220 nm. 
PPAR activation assay 
The general protocol for the PPAR cell-based reporter gene assay has 
been described previously 119,331. The human PPAR-GAL4 chimeric 
receptor expression constructs were as described previously [8]. The 
(UAS),-tk-SPAP reporter plasmid was generated by inserting five 
copies of a GAL4 DNA-binding element upstream of the minimal pro- 
moter of herpes simplex virus thymidine kinase into the pSPAP vector 
that contains the heat-stable human secreted placental alkaline phos- 
phatase (SPAP) reporter gene [34,35]. CV-1 cells (24 000) were 
plated into 96-well plates and transfected with 2 ng of receptor expres- 
sion plasmid, 8 ng of reporter plasmid, 25 ng of bgalactosidase 
expression plasmid (pCH1 10, Pharmacia), and 45 ng of carrier plasmid 
using the Lipofectamine protocol (Life Technologies). After 16 h, the 
medium was exchanged to DME medium supplemented with 10% 
delipidated fetal calf serum (Sigma). A 1 pl aliquot of the fibrate library 
was diluted to a concentration of 5 pM with DME medium and added 
to the cells. After an additional 24 h, cell extracts were prepared and 
assayed for alkaline phosphatase activity and j3-galactosidase activity 
using standard calorimetric assays as described previously (19,341. 
Alkaline phosphatase activity was corrected for transfection efficiency 
using the 5-galactosidase activity as internal standard. Fold activation 
relative to vehicle treated control was calculated and expressed as per 
cent relative to GW 2331 at 10 FM. To generate full concentration- 
response curves the assay was performed using aliquots of the test 
compound diluted at l/2 log concentrations from 10 nM to 10 JIM. 
EC,, equals the concentration of compound required to induce 500/o 
of the maximum alkaline phosphatase activity. 
Saturation binding of PHIGW 2433 
Using 96-well culture plates, 50 nM purified human PPARG LBD and 
the desired concentration of [3H]GW 2433 were diluted to a total 
volume of 100 ul with buffer consisting of 50 mM KCI, 5 mM EDTA, 
10 mM dithiothreitol (DTT), 50 mM HEPES, at pH 7. Saturation 
binding assays were conducted using concentrations of [sH]GW 
2433 ranging from 1 to 250 nM. Nonspecific binding at each concen- 
tration of [sH]GW 2433 was estimated in parallel incubations contain- 
ing 50 pM unlabeled GW 2433. Plates were incubated for 2 h at 
room temperature. Free ligand was separated from receptor-bound 
ligand by size exclusion chromatography using commercially available 
96-well format spin columns. Samples (50 ul) from each well of a 
single test plate were loaded onto a buffer- and temperature-equili- 
brated 96-well gel filtration block (Advanced Genetics Technology 
Corporation). The block was placed on top of a clean microtiter plate 
and centrifuged at 1 100 g for 4 min. Scintillation fluid (180 pl) was 
added to each well of the plate containing the eluent, and the plates 
were sealed and allowed to equilibrate for at least 4 h before counting 
in a Wallac 1450 Microbeta counter. The amount of nonspecific 
binding at each concentration of [3H]GW 2433 was subtracted from 
all wells and plots of [3H]GW 2433 concentration versus counts per 
minute (cpm) bound were constructed. The K, values for i3H]GW 
2433 were determined from a nonlinear least squares fit of the data to 
a simple binding model. 
Competition-binding assay 
Competition-binding curves for GW 2433 were determined with 
expressed human PPARo, PPARy and PPARG LBDs under the same 
conditions used for the saturation binding experiments. Assays were 
conducted in the presence of 0.17 nM to 10 pM of GW 2433 in the 
presence of 20 nM of the specific radioligand. L3H]GW 2331 was 
employed for PPARcx [8], 13H]BRL 49653 for PPART [lQ], and 
13H]GW 2433 for PPARG. The amount of nonspecific binding, as 
assessed by control wells containing 50 pM of the corresponding unla- 
beled ligand, was subtracted from each data point. Plots of GW 2433 
concentration versus cpm of radioligand bound were constructed. 
Apparent Ki values were estimated from a nonlinear least squares fit of 
the data assuming simple competitive binding. 
Supplementary material 
Details of the synthesis and analytical data for the Ml monomers (l-3) 
and the radioligand precursor (12) are published with this paper on the 
internet. 
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